

1 April 2022

## CMBI Credit Commentary – HPDLF

# HPDLF: Concerns on auditor change largely mitigated, maintain Buy on HPDLFs

## Buy on HPDLPs and we like HPDLF 8%'23 (CB) most

Maintain Buy on HPDLFs in view of its adequate liquidity profile, high asset quality and manageable debt maturity profile. Offered at 82 and 80, HPDLP 6.8%'23 and 7%'24 are trading at YTM of 19.5% and 18.9%, respectively. Additionally, we consider Hopson's CB, HPDLF 8%'23, maturing at Jan'23, a good short-dated play. At 90, the CB is trading at an annualized YTM of 23.5% with a higher coupon rate (8%) than those of the 2 straight bonds.

## Unaudited or audited?

We notice that Hopson did not use the word "audited consolidated" for its preliminary FY21 results. Instead, the company mentioned the results were reviewed by its audit committee (comprised of 3 its INEDs), and the preliminary results have been agreed by E&Y. The approach is largely the same as China SCE which is also audited by E&Y. Indeed, Hopson used similar wordings for its preliminary FY20 results. As per our discussions with Hopson (as well as China SCE), and a member of Hopson's audit committee, the FY21 results were audited and reviewed by E&Y. Hopson mentioned that the auditor will have unqualified opinions on its the final FY21 results.

## FY21 results dragged by investment losses, but margin remains high

In FY21, Hopson's revenue and net core profit declined 10.6% and 62.8% to HKD30.7bn and HKD4.8bn, respectively. These were mainly attributable to the investment losses of HKD3.0bn in FY21 (vs gain of HKD8.0bn) from its investment portfolio. We estimate that its revenue and net core profit would increase 28% and 3% to cHKD34bn and HKD7bn, respectively if taking out the investment gain/losses. We are not too concerned of its investment portfolio, as cHKD9bn out of the investment portfolio of HKD15bn are invested in listed and large-cap equities in HK and the US.

**Glenn Ko, CFA** 高志和 (852) 3657 6235 glennko@cmbi.com.hk

**Polly Ng** 吴宝玲 (852) 3657 6234 pollyng@cmbi.com.hk

James Wen 温展俊 (852) 3757 6291 jameswen@cmbi.com.hk

**CMBI Fixed Income** fis@cmbi.com.hk



Its gross margin remains at the very high end of the sector, despite lowered to 43% in FY21 from 64% in FY20. Adjusted for the investment gain/losses, the decline of margin would be more moderate to 48% in FY21 from 52% in FY20. The high margin of Hopson reflects its sizeable, low-cost and high asset quality land bank. This also reflects its slow asset churn model and more manageable debt maturity profile, as such it does not face the pressure to cut price for shoring up liquidity. Taking cues from its contracted ASP of HKD47,087/sqm and unrecognized sales ASP of cHKD18,100 (vs recognized ASP of 17,985/sqm in FY21) in FY21, we expect the margin of Hopson to remain high. Hopson set its FY22 sales target at cHKD56bn, c7% growth from the FY21 sales. For the 2M22, Hopson's contract sales were cHKD4bn, down 10% yoy.

## Green camp under 3 Red Lines

Hopson reduced net debts of HKD4.7bn during FY21, reflected its positive free cash flow. It maintains in the green camp under 3 Red lines with net gearing, adj liab/assets and cash/ST debts ratio at 73.5%, 63.2% and 1.1x in Dec'21, compared with 89.7%, 64.4% and 1.1x in Dec'20, respectively. It does not have outstanding onshore bonds and MTN. its next 12-month public offshore maturities are HKD720mn due Jul'22 and the CBs of USD250mn due Jan'23. Its debt maturity profile is manageable factoring into cash/ST debt ratio of 1.1x, and its investment portfolio of cHKD15bn, cHKD9bn of which are in liquid and listed equities.

CMB International Securities Limited

Fixed Income Department Tel: 852 3761 8867/ 852 3657 6291 fis@cmbi.com.hk

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

#### **Author Certification**

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report abusiness days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

#### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

#### Disclaimer

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

#### For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it

shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.